Medline Tracy Warehouse Destroyed in Fire; Short-Term Disruption Expected
The company is activating contingency plans, which may cause short-term supply disruptions. Analysts expect limited long-term impact.
/ 242 items
#XY Event-Driven Stocks↓
MBX Biosciences’ Canvuparatide Shows Solid One-Year Data but Misses Market Expectations
MBX reports 57% response at 1 year for canvuparatide in hypoparathyroidism with stable safety, but shares fell on modest results.
Adial Pharmaceuticals Acquires Azora and Raises Up to $64 Million for New Ulcerative Colitis Drug
Adial Pharmaceuticals acquires Azora Therapeutics and raises up to $64 million to advance AT177, a novel colon-targeted therapy for ulcerative colitis. Phase 1 studies planned for mid-2027.
Enliven Therapeutics’ ELVN-001 Delivers Strong Results in Phase 1 CML Study, Aligns with FDA on Phase 3 Design
Early results show performance that is comparable to a widely used Novartis blockbuster and a Merck-owned experimental treatment.
Humacyte Shares Slide on Stock Sale Despite Positive Dialysis Trial Data
Humacyte shares dropped following a $50M stock offering announcement. The move comes even as the company reported strong interim Phase 3 data for its ATEV in female dialysis access patients.
Clover Health Triumphs in Court – Massive 4.5-Star Medicare Rating Upgrade
Clover Health got its Medicare rating raised to 4.5 stars, boosting future government bonus payments from 2027.